Using HCV-viremic organs for lung transplantation does not confer higher rejection rates compared to HCV-negative organs.

We demonstrate the feasibility and success of using HCV NAT + donors with excellent results and without a higher incidence of rejection. Longer term follow-up and a larger sample size are needed to allow this to be a more widely accepted practice for lung transplant programs and payors.